Document is current

Article History

Received: 20 February 2026

Accepted: 2 June 2026

First Online: 17 June 2026

Declarations

Ethics approval: The study was approved by the Ethics Committee of the University of Würzburg (AZ 119/22) and conducted in accordance with the Declaration of Helsinki.

Consent to participate: All participants provided written informed consent for study participation and publication of anonymized data.

Consent for publication: All included patients gave their consent for publication of the collected data.

Competing interests: AF received honoraria from GSK, BMS and Janssen. JW: Consultancy for Johnson&Johnson, Sanofi, Take¬da, Pfizer, Oncopeptides, Skyline Dx; Honoraria from GSK, Johnson&Johnson, Pfizer and Beigene; Research support from BMS. LR received honoraria from Amgen, BMS, GSK, Janssen, Sanofi, and Pfizer and research funding from BMS. The remaining authors declare no conflicts of interest. KMK received Honoraria from Abbvie, Beigene, BMS, GSK, Johnson&Johnson, Menarini, Novartis, Pfizer and Sanofi. CS: consultancy for Acus Health, Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer; honoraria from Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Takeda, Sanofi; other (travel expenses/congress support): Acus Health, Astra Zeneca, BeOne, Janssen-Cilag, Menarini Stemline, oncopeptides, Sanofi. AG served as consultant and/or has received honoraria or travel costs from Allmiral, Amgen, Bristol-Myers Squibb, Immunocore, MSD Sharp & Dohme; Novartis, Pierre Fabre Pharmaceuticals, Pfizer, Regeneron, Roche and Sanofi Genzyme, outside the submitted work.